What top creators are saying about Royalty Pharma(RPRX)

An investor in biopharmaceutical royalties.

3 AI-extracted insights from 3 sources — podcasts, YouTube channels, and X/Twitter accounts.

Creator sentiment — last 30 days

Based on 2 scored insights about Royalty Pharma.

Bullish
avg +0.15
1 bullish1 neutral0 bearish

Top creators covering Royalty Pharma (RPRX)

The 3 sources with the most insights about Royalty Pharma on Kazuha.

Latest insights about Royalty Pharma (RPRX)

AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.

Monday, October 12, 2026

Bullish

Shkreli distinguished its royalty-acquisition model from drug development and cited a successful historical Remicade royalty purchase, without giving a current valuation view.

Neutral

Presented as a distinctive drug-royalty investment model, with a historical Remicade royalty success; no current valuation or stock recommendation was provided.

Tuesday, September 9, 2025

Neutral

A large shareholder has been selling, but their timing has been poor as the stock continued to rise, indicating the sales carry little predictive signal.

Discussed alongside Royalty Pharma (RPRX)

Other assets that creators frequently mention in the same content as Royalty Pharma.

Frequently asked

Which podcasters and creators cover Royalty Pharma (RPRX) the most?

The most active sources covering Royalty Pharma (RPRX) on Kazuha are @ceowatcher, @allin, All-In Podcast, LLC. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.

How many insights about Royalty Pharma (RPRX) are on Kazuha?

Kazuha has indexed 3 AI-extracted insights about Royalty Pharma (RPRX) from 3 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.

What other assets do creators discuss alongside Royalty Pharma (RPRX)?

Creators covering Royalty Pharma (RPRX) most frequently also discuss OpenAI, OptiCore, BMY, Remicade, META. See the "Discussed alongside" section above for full asset pages.